HZNP Horizon Therapeutics Public Limited Company

23.36
-0.15  -1%
Previous Close 23.52
Open 23.52
Price To Book 2.87
Market Cap 4,319,811,880
Shares 184,883,881
Volume 304,306
Short Ratio
Av. Daily Volume 2,089,045

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)
BLA filing announced July 10, 2019.
Teprotumumab
Thyroid Eye Disease (TED)
Phase 2 trial initiation announced September 27, 2018.
Krystexxa with Methotrexate
Gout
Randomized trial initiation announced June 20, 2019.
Krystexxa with Methotrexate - MIRROR RCT
Gout

Latest News

  1. Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
  2. Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes
  3. Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
  4. Horizon Therapeutics plc Announces Proposed Private Offering of Senior Notes
  5. Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
  6. Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
  7. Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
  8. Eyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease
  9. Is There An Opportunity With Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) 50% Undervaluation?
  10. Here’s What Hedge Funds Think About Horizon Therapeutics Public Limited Company (HZNP)
  11. Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
  12. See what the IHS Markit Score report has to say about Horizon Therapeutics PLC.
  13. Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019
  14. How Should Investors Feel About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Pay?
  15. Horizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference
  16. Edited Transcript of HZNP earnings conference call or presentation 8-May-19 12:00pm GMT
  17. Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
  18. Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE
  19. Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout